Neowise Biotechnology ("Neowise"), a pioneering company focused on the development of TCR-T cell therapies for solid tumors, announced today that it has entered into a non-exclusive licensing agreement with BeOne Medicines Ltd. ("BeOne"). Under the terms of the agreement, Neowise will grant BeOne rights to one of its proprietary antigen-specific TCR molecules for the development of next-generation, iPSC-based off-the-shelf cell therapies.

Under the terms of the agreement, Neowise will receive an upfront payment and will be eligible for future milestone payments based on the achievement of certain development, regulatory, and commercial milestones, in addition to royalties. BeOne will have the right to develop and commercialize its next-generation cell therapy products using the licensed TCR.

"We are very pleased to enter into this agreement with BeOne, which will expand the application of our TCR molecules into new territories and support the research and clinical development of BeOne's next-generation cell therapy products," said Songming Peng, Ph.D., Founder and CEO of Neowise. "With our expertise in antigen-specific TCR discovery, we believe in the great commercial value and broad clinical potential of our proprietary antigen-TCR library, CAST^®. We look forward to working with BeOne to bring next-generation, off-the-shelf cell therapies to cancer patients worldwide."

"As a global company committed to advancing the next frontier of cancer treatment, BeOne is harnessing the transformative potential of iPSC-derived cell therapies in oncology," said Alex Huang, Ph.D., Vice President and Head of Cell Therapy at BeOne. "We are building an allogeneic, off-the-shelf cell therapy platform that uses cutting-edge genetic engineering to achieve broad applicability across diverse patient populations - bringing us closer to more universal, accessible cancer treatments. To accelerate this vision, we are actively forging strategic, global partnerships. Our collaboration with Neowise represents a powerful step forward in delivering next-generation cell therapies that expand and elevate treatment options for patients worldwide."